Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?

European Heart Journal: Acute Cardiovascular Care

Volumn 6, Issue 4, 2017, Pages 321-328

  Mair, Johannes ^a   Lindahl, Bertil ^b   Giannitsis, Evangelos ^c   Huber, Kurt ^d   Thygesen, Kristian ^e   Plebani, Mario ^f   Möckel, Martin ^g   Müller, Christian ^h   Jaffe, Allan S ⁱ  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d WILHELMINEN HOSPITAL   (Austria)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ MAYO CLINIC   (United States)

Author keywords

acute cardiac care; B type natriuretic peptide; diagnosis; heart failure; natriuretic peptides; Sacubitril valsartan

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TETRAZOLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); GENETIC TRANSCRIPTION; HEART FAILURE; HUMAN; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; UPREGULATION; ANTAGONISTS AND INHIBITORS; BLOOD; CHRONIC DISEASE; DRUG EFFECTS; HEART STROKE VOLUME; MALE; METABOLISM; PHYSIOLOGY; PREDICTIVE VALUE;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CHRONIC DISEASE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; NEPRILYSIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; STROKE VOLUME; TETRAZOLES;

EID: 85050579440     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872615626355     Document Type: Article

References (39)

1. McMurray JJ, Packer M, Desai AS.; PARADIGM_HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004.
2. Mangiafico S, Costello-Boerritger LC, Andersen IA. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013; 34: 886–893.
3. Volpe M, Rubattu S, Burnett J, Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 2014; 35: 419–425.
4. Song W, Wang H, Wu Q., Atrial natriuretic peptide in cardiovascular biology and disease. Gene 2015; 569: 1–6.
5. Potter R., Natriuretic peptide metabolism, clearance and degradation. FEBS Journal 2011; 278: 1808–1817.
6. Goetze JP, Hansen LH, Terzic D. Atrial natriuretic peptides in plasma. Clin Chim Acta 2015; 443: 25–28.
7. Mair J., Biochemistry of B-type natriuretic peptide – where are we now? Clin Chem Lab Med 2008; 46: 1507–1514.
8. Ala-Kopsala M, Magga J, Peuhkurinen K. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004; 50: 1575–1588.
9. Ichiki T, Huntley BK, Sangaralingham JS. Pro-atrial natriuretic peptide. J Am Coll Cardiol HF 2015; 3: 715–723.
10. Mair J., Clinical significance of pro-B-type natriuretic peptide glycosylation and processing. Clin Chem 2009; 55: 394–347.
11. Hammerer-Lercher A, Halfinger B, Sarg B. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008; 54: 858–865.
12. Semenov AG, Postnikov AB, Tamm NN. Processing of pro-brain natriuretic peptide is suppressed by o-glycosylation in the region close to the cleavage site. Clin Chem 2009; 55: 489–498.
13. Vodovar N, Seronde MF, Laribi S. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 2014; 35: 3434–3441.
14. Seferian KR, Tamm NN, Semenov AG. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008; 54: 866–873.
15. Niederkofler EE, Kiernan UA, O’Rear J. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008; 1: 258–264.
16. Thygesen K, Mair J, Mueller C.; Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012; 16: 2001–2006.
17. McMurray JJ, Adamopoulos S, Anker SD.; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–1847.
18. Maisel AS, Krishnaswamy P, Nowak RM.; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–167.
19. Januzzi JL, Jr Camargo CA, Anwaruddin S. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948–954.
20. Maisel A, Mueller C, Nowak R. Mid-regional pro-hormone markers for diagnosis and prognosis in acute dyspnea. J Am Coll Cardiol 2010; 55: 2062–2076.
21. Mueller D, Schulze C, Baumeister H. Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. Biochemistry 1992; 31: 11138–11143.
22. Vodovar N, Seronde MF, Laribi S.; GREAT Network. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. J Am Coll Cardiol HF 2015; 3: 629–636.
23. Pankow K, Schwiebs A, Becker M. Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol 2009; 393: 496–503.
24. Watanabe Y, Nakajima K, Shimamori Y. Comparison of hydrolysis of the three types of natriuretic peptides by human kidney neutral peptidase 24.11. Biochem Mol Med 1997; 61: 47–51.
25. Belenky A, Smith A, Zhang B. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004; 340: 163–172.
26. Gu J, Noe A, Chandra P. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401–414.
27. Packer M, McMurray JJ, Desai AS.; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131: 54–61.
28. Vorderwinkler KP, Artner-Dworzak E, Jakob G. Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac diseases. Clin Chem 1991; 37: 186–190.
29. Solomon SD, Zile M, Pieske B. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387–1395.
30. Schou M, Gustafsson F, Nielsen PH. Unexplained week-to-week variation in BNP and NT-proBNP i slow in chronic heart failure patients during steady state. Eur J Heart Fail 2007; 9: 68–74.
31. Fokkema MR, Herrmann Z, Muskiet FAJ. Reference change values for brain natriuretic peptide revisited. Clin Chem 2006; 52: 1602–1603.
32. Hoofnagle AN, Whiteaker JR, Carr SA. Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays. Clin Chem 2016; 62: 41–47.
33. Morgenthaler NG, Struck J, Thomas B. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234–236.
34. Luckenbill KN, Christenson RH, Jaffe AS. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008; 54: 619–621.
35. Tamm NN, Semenov AG, Seferian KR. Measurement of B-type natriuretic peptide by two assays utilizing antibodies with different epitope specificity. Clin Biochem 2011; 44: 257–259.
36. Roberts E, Ludman AJ, Dworzynski K. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute setting. BMJ 2015; 350: h910. doi: 10.1136/bmj.h910
37. Cohen-Solal A, Logeart D, Huang B. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009; 53: 2343–2348.
38. Salah K, Kok WE, Eurlings LW. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European collaboration on acute decompensated heart failure: ELAN-HF Score. Heart 2014; 100: 115–125.
39. Kociol RD, Horton JR, Fonarow GC. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 2011; 5: 628–636.